Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157683 | 0.82 | PIM1 (0.37) | KDM4ELMNARXFP1ALDH1A1HPGD | |
| SCHEMBL4157599 | 0.79 | IDH1 (0.35) | KDM4ELMNARXFP1ALDH1A1HPGD | |
| SCHEMBL4154216 | 0.78 | SHMT2 (0.38) | KDM4ERXFP1MEN1KMT2AHSD17B10 | |
| SCHEMBL11049306 | 0.77 | CRHBP (0.34) | KDM4ELMNARXFP1HPGDCYP2C19 | |
| SCHEMBL4159917 | 0.77 | DYRK1A (0.47) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4156006 | 0.77 | CCNA2 (0.35) | KDM4ELMNAHPGDCYP2C19PDE5A | |
| SCHEMBL10967371 | 0.77 | PIM1 (0.38) | KDM4ERXFP1PARP1 | |
| SCHEMBL4163224 | 0.75 | NPC1 (0.41) | KDM4ERXFP1ALDH1A1HPGDMEN1 | |
| SCHEMBL4166635 | 0.74 | PARP1 (0.36) | KDM4EMEN1KMT2AHSD17B10PARP1 | |
| SCHEMBL4154240 | 0.73 | PIM1 (0.36) | KDM4ELMNAALDH1A1KMT2APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713457-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-10-25 | — | — | EP | claimed |
| WO-2005077343-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2005-08-25 | — | — | WO | claimed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2009-05-07 | — | — | US | disclosed |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2009-05-07 | — | — | US | disclosed |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1713457-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077343-A9 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX DELBRUECK CENTRUM (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005077343-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | APP, PSEN2, PSEN1 | CSNK2A1 2584/4885KDM4E 4827/4885LMNA 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.